HER2 Support Group Forums - View Single Post - MESUPRON® Met Its Primary Objective Of Demonstrating Efficacy In The Proof Of Concept

News · 06-19-2012, 01:13 AM

WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) published data last week from its Phase II trial with its oral drug candidate MESUPRON® in first line treatment of patients with HER2-receptor negative metastatic breast cancer...

More...

06-19-2012, 01:13 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,959	MESUPRON® Met Its Primary Objective Of Demonstrating Efficacy In The Proof Of Concept WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) published data last week from its Phase II trial with its oral drug candidate MESUPRON® in first line treatment of patients with HER2-receptor negative metastatic breast cancer... More...